Singapore Reports Surge in Cases
Singapore is experiencing an outbreak of chikungunya cases, with over 20 reported infections since January 2025—double the typical rate. The outbreak continues to escalate with more than one case per week since early August, but health officials say it has not yet peaked.
France Experiences First Chikungunya Outbreak
According to Santé Publique France, approximately 70 locally acquired cases of chikungunya have been reported since mid-June 2025—a significant increase over average incidence. This marks the first chikungunya outbreak in France. Health officials have reported cases distributed across multiple regions including Provence-Alpes-Côte d’Azur (22 cases), Corsica (13 cases), Occitanie (16 cases), Nouvelle-Aquitaine (3 cases), Auvergne-Rhône-Alpes (7 cases), and Grand Est (1 case) regions.
Italy Reports Local Transmission Clusters
Italy has confirmed four local transmission events of chikungunya virus in the northern regions of Emilia-Romagna and Veneto, with 29 locally acquired cases reported by August 20, 2025. This represents a concerning development as it demonstrates active local transmission in two separate outbreak clusters in northern Italy.
What Travelers Need to Know and Protection Measures
Travelers should be aware that chikungunya is a mosquito-borne viral infection causing fever, severe joint pain, and muscle aches that can persist for weeks or months.
All travelers to areas endemic for chikungunya should take comprehensive mosquito protection measures, including using EPA-approved insect repellents, wearing light-colored long sleeves and pants when possible, and staying in air-conditioned or screened accommodations. Be especially vigilant during peak mosquito activity times: early morning, late afternoon, and evening, though the Aedes mosquitoes that transmit chikungunya can bite throughout the day. Travelers aged 12 and older should consult their healthcare provider about chikungunya vaccination before departure. Seek immediate medical attention if you develop sudden fever, joint pain, or rash during or after your trip.
Important Update on Chikungunya Vaccination:
The Ixchiq® chikungunya vaccine, developed by Valneva, has recently been withdrawn from the U.S. market following reports of rare but serious vaccine-related side effects. While this may seem concerning, it also demonstrates that the U.S. vaccine safety monitoring system is working effectively to protect public health.
At TravelBug Health, your safety is our top priority. We offer Vimkunya®—an alternative chikungunya vaccine option with a safer side effect profile and strong protection for international travelers visiting regions where there is a Chikungunya outbreak.
Schedule a consult with TravelBug Health to have a discussion about whether the Chikungunya vaccine is right for you.
To learn more about Chikungunya, visit our Chikungunya vaccination page.
